Psychedelics – News and Features

Repeated intravenous ketamine infusions significantly reduce symptom severity in individuals with chronic post-traumatic stress disorder (PTSD) and the improvement is rapid and maintained for several weeks afterwards, according to a new study

Substance use disorders have a debilitating impact on the wellbeing of individuals and their families. Like many other mental health disorders, these conditions have proved stubbornly resistant to treatment. New clinical trials are exploring the safety of the psychedelic DMT for the treatment of these disorders.

New efforts are trying to tease out what would be a minimal effective dose of psilocybin, one that would have beneficial effects on the brain whilst minimizing hallucinatory experiences.

Anon-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis.

Researchers have discovered a protein group that is key to unlocking the antidepressant effect of ketamine in the brain.

The world’s first clinical trial testing the efficacy of the psychedelic compounds N,N-dimethyltryptamine (DMT) has won approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

New research shows how prehistoric indigenous American people created rock art as part of the hallucinogenic experience.

Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? Technology Networks talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more.

The role that psychedelic therapeutics could play in tackling many intractable mental health conditions has finally been recognized by mainstream medicine. To find out more, we spoke to Carol Routledge, Chief Medical & Scientific Officer at Small Pharma.

Dimethyltryptamine, a central component of the naturally psychedelic drink ayahuasca tea, can boost the formation of new neurons, a new study has found.